Back

Safety and efficacy of treatment with mavacamten for up to 5 years in patients with obstructive hypertrophic cardiomyopathy: final results from MAVA-LTE

29 August 2026 (17:00 - 17:15)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Anjali Owens

University of Pennsylvania, Philadelphia (United States of America)

3 More presentations in this session

Presentation thumbnail
Effect of aficamten on cardiac structure and function in patients with symptomatic nonobstructive hypertrophic cardiomyopathy - Results from the ACACIA-HCM trial
Doctor S. Hegde (Dallas, US)
Slides Video
Presentation thumbnail
Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM
Doctor F. Dominguez (Madrid, ES)
Slides Video
Presentation thumbnail
Deep Learning Model for Detection, Phenotyping, and Left Ventricular Gradient Estimation in Hypertrophic Cardiomyopathy Using Echocardiography: Development and Multinational External Validation
Doctor F. Alenezi (Durham, US)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Clinical Science: hypertrophic cardiomyopathy
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 17:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study
1 September 2024
thumbnail
Congress Presentation
ACACIA-HCM: Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy
28 August 2026
thumbnail
Congress Session
Late-breaking science on valve disease and hypertrophic cardiomyopathy
28 August 2023
thumbnail
Congress Presentation
Real-world symptom and echocardiographic improvement in obstructive HCM patients treated with mavacamten: evidence of favorable disease modification
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources